Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer

Bo Jiang, Xin Zhang, Li-Li Du, Yan Wang, Dong-Bo Liu, Cun-Zhi Han, Jie-Xian Jing, Xian-Wen Zhao, Xiao-Qin Xu

Abstract

AIM: To investigate the roles of serum insulin, insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding proteins (IGFBPs) in the initiation and progression of colorectal cancer.

METHODS: We determined serum insulin, IGF-1 and IGFBPs levels in 615 colorectal cancer patients and 650 control healthy donors by enzyme-linked immunosorbent assay (ELISA). In the meantime, their body mass index (BMI) and waist-to-hip ratio (WHR) were measured.

RESULTS: Serum levels of insulin and IGF-1 as well as IGF-1/IGFBP-3 ratio in pre-operation patients were significantly elevated, but the level of IGFBP-3 was significantly decreased compared with normal controls and post-operation patients ($P < 0.05$ and $P < 0.001$, respectively). There is no significant difference ($P > 0.05$) in the levels of insulin, IGF-1, IGFBP-1, IGFBP-3 and IGF-1/IGFBP-3 between the patients with and without hepatic as well as distal abdominal metastases. WHR and BMI of colon cancer patients were positively and significantly correlated with the levels of insulin and IGF-1/IGFBP-3. In contrast, WHR and BMI were negatively correlated with IGFBP-3 level.

CONCLUSION: The elevation of insulin, IGF-1 as well as IGF-1/IGFBP-3 ratio and the reduction of IGFBP-3 may be related to the initiation of colorectal cancer, but they are not related to the progression and outcome of the disease.

Key words: Colorectal cancer; Insulin; Insulin-like growth factor-1; Insulin-like growth factor binding protein-3; Insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio

Core tip: A previous study evaluated the effects of insulin, IGF-1 and IGFBPs on cell growth and proliferation, which played important roles in the etiology of colon cancer. The present study aimed to investigate the relationship of changes in serum insulin, IGF-1, IGFBPs, body mass index, waist-to-hip ratio with the initiation and progression of colorectal cancer. We observed that there were no differences in serum levels of leptin, IGF-1, IGFBP-1 and IGFBP-3 as well as IGF-1/IGFBP-3 ratio between pre- and post-operation colorectal cancer patients.

Jiang B, Zhang X, Du LL, Wang Y, Liu DB, Han CZ, Jing JX, Zhao XW, Xu XQ. Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer. World J Gastroenterol 2014; 20(6): 1608-1613. Available from: URL: http://
www.wjgnet.com/1007-9327/full/v20/i6/1608.htm  DOI: http://dx.doi.org/10.3748/wjg.v20.i6.1608

INTRODUCTION

Reports in recent years showed that the rate of colorectal cancer in North America is 44.60/100 thousand, while in Europe is 42.9/100 thousand[9]. Based on the investigations from the Asian-Pacific colorectal cancer collaborative group, the incidences of colorectal cancer significantly increased in several Asian countries. The rates of colorectal cancer in Japan, South Korea and Singapore are 49.3/100 thousand, 24.7/100 thousand and 35.1/100 thousand, respectively. With the improvement of the quality of life of the Chinese people and changes in their diet, the incidence of colorectal cancer is increasing, especially in large cities[2-4]. The high incidence of colorectal cancer may be associated with genetics, environment, lifestyle and diet. Previous studies showed that both insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) genes had no association with the occurrence of colon cancer, while insulin receptor substrate-1 (IRS-1) had certain association with colon cancer incidence[5-8]. There are very few reports on the association of biomarkers such as insulin, IGFBP-1 and IGFBPs with the incidence of colorectal cancer in China. In this study, we investigated risk factors associated with colorectal cancer, and the relationship between IGF-1, IGFBPs and colorectal cancer. Our results may provide insights into the causes of the increased incidence of colorectal cancer in China.

MATERIALS AND METHODS

Study population and recruitment procedure

A total of 615 hospitalized patients or revisited outpatients who were diagnosed with colorectal cancer in the Department of Anorectal Surgery of Shanxi Cancer Hospital from June 2010 to October 2011 were recruited for this study. All participants answered the inquiry questions. The study was approved by the Ethics Committee of Shanxi Cancer Hospital. There were 335 male and 280 female patients with a median age of 53 years old (range, 20 to 80 years old). There were 193 cases of colon cancer (pre-operation 73 cases and post-operation 120 cases), and 410 cases of rectal cancer (pre-operation 199 cases and post-operation 211 cases). There were also 12 cases of colorectal junction cancer. All pre-surgical patients received no treatment, and all post-surgical patients were confirmed with colon or rectal ulcer-cancer, infiltrating cancer or junction cancer by histopathological examination. There were 650 healthy participants as controls, including 368 males and 282 females with a median age of 49 years old (range, 18 to 72 years old). All patients and healthy controls had no history of diabetes. The data for the patients are shown in Table 1.

Data collection

A trained nurse measured the weight (kg), height (cm), and waist and hip circumferences (cm) and collected 10 mL of blood from the pre- and post-operation patients. Information about the risk factors for colorectal cancer was collected by trained interviewers. The investigation questionnaire included age, occupation, education, ethnic group, residence, history of benign colorectal diseases and malignant tumors. Body measurements include height, weight, waist and hip circumferences, and blood pressure.

Analysis of serum insulin, IGF-1, IGFBPs, and leptin

At the time of blood collection, blood constituents were rapidly aliquoted and levels of insulin, IGF-1, IGFBPs and leptin were assayed by ELISA within 48 h. All reagents were provided by American ADL Company and Swedish Mercodi AB Company. Serum leptin levels were assayed by using Human Radioimmunoassay RIA kit (Linco Research, St. Louis, United States). All the procedures were according to the manufacturers’ instructions.

Statistical analysis

The survey and the experimental data were statistically analyzed with SPSS13.0 software. The differences between groups were analyzed by t-test, \( \chi^2 \) tests, variances and correlations. Analyzed data are shown as mean ± SD, and the differences were considered significant when \( P < 0.05 \).

RESULTS

All subjects were local Shanxi residents with 10 or more years of residency and belong to Han ethnic group. The average age of colorectal cancer patients was 53.85 ± 13.99, while the average age was 49.72 ± 9.95 for the healthy control group. There was no statistical difference in age between the two groups. There were also no statistical differences in occupation (\( \chi^2 = 10.20, P = 0.08 \)), education (\( \chi^2 = 1.588, P = 0.66 \)), residence location (\( \chi^2 = 0.37, P = 0.59 \)) or blood pressure (\( \chi^2 = 0.20, P = 0.78 \)).

Comparison of serum levels of leptin, insulin, IGF-1, IGFBP1 and IGFBP3 between colorectal patients and healthy controls

The levels of serum leptin, insulin, IGF-1 and IGF-1/IGFBP3 in colorectal cancer patients were significantly

| Table 1 Patient and disease characteristics |
|-------------------------------------------|
| **Characteristic** | **n** |
|-------------------|------|
| Gender            | 335/280 |
| Male/female       |      |
| Clinical Stage    | 60/362/193 |
| T1/T2/T3          |      |
| Type              | 193/410/12 |
| Colon cancer/rectal cancer/colorectal cancer |      |
| Colon cancer      | 53/140 |
| Pre/post-operation|      |
| Rectal cancer     | 179/231 |
| Pre/post-operation|      |
| Health control    | 368/282 |
| Male/female       |      |
Table 2 Comparisons of pre-operation and post-operation serum levels of biomarkers between colorectal cancer patients and healthy controls (x bar ± s)

| Biomarker    | Healthy controls (n = 650) | Pre-operation (n = 284) | Post-operation (n = 331) |
|--------------|---------------------------|------------------------|--------------------------|
| Insulin (μIU/mL) | 6.24 ± 4.70               | 9.82 ± 4.67            | 9.97 ± 6.01              |
| IGF-1 (ng/mL)   | 136.73 ± 63.17            | 200.16 ± 44.07         | 209.84 ± 47.82           |
| IGFBP-1 (μg/mL)| 10.97 ± 3.58              | 12.23 ± 4.03           | 12.54 ± 4.31             |
| IGFBP-3 (μg/mL)| 9.24 ± 3.91               | 6.47 ± 3.05            | 7.05 ± 2.31              |
| IGF-1/IGFBP-3   | 29.01 ± 10.02             | 39.02 ± 16.35          | 31.98 ± 13.49            |
| Leptin (ng/mL)  | 9.01 ± 4.97               | 13.49 ± 8.35           | 13.79 ± 8.35             |

1Compared to healthy controls, P < 0.001 and P < 0.05; 2Healthy controls compared to pre- and post-operation groups, which showed significant differences, P = 0.015 and P = 0.001; 3Pre-operation group compared to post-operation group, P = 0.02. IGF-1: Insulin-like growth factor-1; IFGBP1: Insulin-like growth factor binding protein.

higher than those in healthy controls, while the IGFBP-3 level was lower than controls (P < 0.05 and P < 0.001, respectively). There was no significant difference in IGFBP-1 levels between the two groups (P > 0.05). IGFBP-3 level was obviously lower in pre-operation patients than in post-operation patients, and the IGF-1/IGFBP-3 ratio was significantly higher in pre-operation patients (P < 0.05). The results are shown in Table 2.

Comparisons of serum levels of leptin, insulin, IGF-1, IGFBP1, IGFBP3 and IGF-1/IGFBP3 between patients with and without metastatic colorectal cancer

Three hundred and five cases of colorectal cancer patients involved, who survived one year, three years and more than three years after surgery. Among them, no metastasis was found by color ultrasonic imaging and computed tomography (CT). Another 66 patients were found with hepatic or abdominal metastases by color ultrasonic imaging and CT. We compared the two groups about serum levels of insulin, IGF-1, IGF-1/IGFBP3, IGFBP1, IGFBP3 and leptin. There were no statistical differences (P > 0.05) between them. The results are shown in Table 3.

Comparisons of serum levels of leptin, insulin, IGF-1 and IGFBPs between colon cancer and rectal cancer patients

The serum levels of IGF-1, IGFBP1 and IGF-1/IGFBP3 ratio were significantly higher in rectal cancer patients than in colon cancer patients (P = 0.041, P = 0.022 and P = 0.033, respectively). There were no statistical differences in leptin, insulin and IGFBP-3 levels between the two groups (P > 0.05). Related data are shown in Table 4.

Comparisons of body mass index and waist-to-hip ratio between colorectal cancer patients and healthy controls

Body mass index (BMI) showed no statistical difference between the two groups (P > 0.05), while waist-to-hip ratio (WHR) displayed a significant difference between cancer patients and controls (P = 0.003 for colon cancer and P = 0.035 for rectal cancer). There was a significant difference in WHR between colon cancer patients and rectal cancer patients (P = 0.046), but there was no difference in BMI between the two groups (P > 0.05). The comparison data are shown in Table 5.

Correlations between the BMI/WHR of the patients and their serum leptin, insulin, IGF-1, IGFBP1 and IGFBP3 levels

WHR and BMI of colon cancer patients were positively correlated with serum levels of leptin, insulin and IGF-1/IGFBP3 ratio, and inversely correlated with IGFBP3 level. There is no correlation between the both and IGF-1 and IGFBP1. Data are shown in Table 5. WHR of rectal cancer patients was positively correlated with serum levels of leptin and IGF-1 (r = 0.213, P < 0.05 and r = 0.291, P = 0.045), while BMI also positively correlated with serum IGFBP1 level (r = 0.333, P = 0.016). There was no correlation between BMI and other biomarkers (P > 0.05). Table 6 shows the comparison data of colon cancer patients.

Comparisons of serum levels of insulin, IGF-1, IGFBPs and IGF-1/IGFBP3 between pre- and post-operation cancer patients

There were significant differences between pre- and post-operation stage T2-T3 cancer patients in the levels of serum insulin, IGF-1, IGFBPs and IGF-1/IGFBP3 ratio (P < 0.05). Related data are shown in Table 7.

DISCUSSION

Colorectal cancer in Shanghai region of China is positively correlated with the consumptions of red meat, fish and preservative containing food\[9-12\]. Mao et al\[13\] investigated the association of physical inactivity, energy intake...
and obesity with risk factors for rectal cancer in 1447 rectal cancer patients and 3106 healthy controls from 7 provinces in Canada. Their results showed that the obvious risk factors for rectal cancer are overweight, obesity and BMI $\geq 30$ kg/m$^2$ with an odds ratio (OR) of 1.44 for females and 1.78 for males. The results also suggest that there is a great increase in risk for the incidence of rectal cancer when high energy intake, high BMI and low physical activity simultaneously exist. Many researchers reached the same conclusion.$^{[4,14-17]}$. In our study, we also found that high BMI and WHR were associated with cancer patients.

Dietary lipids provide a rich source of energy and diets high in lipids, especially animal fat, may increase the risk of colorectal cancer$^{[18,19]}$. And the obesity is associated with serum levels of insulin, IGF, leptin and lipid, among other factors$^{[20,21]}$. Insulin-like growth factors include two polypeptides IGF-1 and IGF-2. IGF-1 is an important mitogen in the body, which promotes cell proliferation and inhibits apoptosis$^{[22,23]}$. There is no report that demonstrated a cause-and-effect relationship between IGF-1 and cancer and no investigator ever suggested that IGF-1 was a causative agent in tumor development. However, it was reported that patients with certain types of tumors had high levels of IGF-1 in their circulation as a manifestation of their disease. The elevated levels of IGF-1 seem to occur very early in tumor development. In our study, we also found high levels of IGF-1 in colorectal cancer patients. It suggested that measurement of IGF-1 in the blood of people may be an early warning indicator that a tumor could be developing in the body.

IGFBP-3 is an apoptosis inducing factor and exerts its roles through competing with IGF-1 for receptor binding and through regulating local concentration of IGF-1. It was shown with increasing evidence that IGFBP-3 could also independently inhibit cell proliferation and induce apoptosis without involving IGFs. Hyperglycemia, hyperinsulinemia, and increased IGF-1 level have already been etiologically proven as risk factors for colorectal cancer$^{[22,23]}$. IGFBPs were also considered as regulators of insulin level$^{[3]}$. Slattery et al$^{[4]}$ evaluated the effects of insulin, IGF-1 and IGFBPs on cell growth and proliferation, which played important roles in the etiology of colon cancer and breast cancer. They also analyzed the relationship of genetic polymorphisms of IRS-1, 2, IGF-1 and IGFBP-3 with colon cancer by genotyping using data collected in a case-control study of 1346 colon cancer cases paired with 1544 controls and 952 rectal cancer cases paired with 1205 controls. The results implied that IRS-1 and the R allele of G927R are risk factors for colon cancer with an OR of 1.4; in the meantime IRS2 and G927R heterozygote GD genotype significantly reduced the colon cancer risk with an OR of 0.8. Wei et al$^{[5]}$ believed that hyperinsulinemia, IGF-1 and IGFBP-3 are involved in the pathogenic mechanism of colon cancer and increased colon cancer risk. They also reported that Western style of life and diet may be the major reasons for increased risk of cancer, especially colon cancer$^{[20,21]}$. Xuan et al$^{[25]}$ also found that insulin level could increase the risk of breast cancer. The main mechanisms may involve reduced plasma and tissue levels of IGFBPs by elevated insulin level (hyperinsulinemia and insulin resistance). Therefore, a subsequently increased IGF-1 activity inhibited cell apoptosis and stimulated cell proliferation activity, and finally induced the rapid growth of tumor cells.

Our results showed that the levels of serum leptin, insulin, IGF-1 and IGF-1/IGFBP3 in colorectal cancer patients were significantly higher than those in healthy controls, while the IGFBP-3 level was lower than controls.

Leptin is the product of the OB gene, and its biological effects are regulating the body weight, maintaining metabolism and keeping energy balance. Leptin promoted colon cell proliferation and cancer initiation$^{[22,23]}$. Investigations from Stattin et al$^{[3]}$ also suggest that leptin may be directly involved in the initiation of colon cancer and may serve as a sensitive biomarker for obesity induced adverse endocrine environment. Liu et al$^{[6]}$ postulated that a high-fat diet enhances colon cell proliferation and carcinogenesis by elevating serum leptin. In their experiments, colon cell proliferation, c-fos protein expression and aberrant crypt foci (ACF) were elevated following increased dietary fat. There was a significant correlation between serum leptin and colon cell proliferation and ACF$^{[6]}$. Our results also

---

**Table 5** Comparisons of body mass index and waist-to-hip ratio between colorectal cancer patients and healthy controls ($x \bar{\pm} s$)

| Group            | Body mass index | WHR  |
|------------------|----------------|------|
| Colon cancer     | 23.99 $\pm$ 3.95 | 0.99 $\pm$ 0.061$^c$ |
| Rectal cancer    | 24.01 $\pm$ 3.62 | 0.90 $\pm$ 0.017$^d$ |
| Healthy controls | 23.26 $\pm$ 2.96 | 0.81 $\pm$ 0.037 $^e$ |

$^c$Comparison of WHR between colorectal cancer patients and healthy controls, $P = 0.003$ and $P = 0.035$. $^d$Comparison of WHR between colon cancer patients and rectal cancer patients, $P = 0.046$. WHR: Waist-to-hip ratio.

**Table 6** Associations of waist-to-hip ratio and body mass index of colon cancer patients with the levels of leptin, insulin, insulin-like growth factor, insulin-like growth factor binding protein-1, insulin-like growth factor binding protein-3 and insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio

| Biomarker         | WHR Pearson correlation | BMI Pearson correlation | $P$ value |
|-------------------|-------------------------|------------------------|-----------|
| Insulin           | 0.519                   | 0.485                  | < 0.001   |
| Leptin            | 0.396                   | 0.448                  | < 0.001   |
| IGF-1             | 0.394                   | 0.172                  | > 0.05    |
| IFGBP-3           | -0.259                  | 0.082                  | > 0.05    |
| IGFBP-3           | -0.443                  | -0.342                 | > 0.05    |
| IGF-1/IGFBP3      | 0.501                   | 0.296                  | 0.045     |

**Note:**
- IGF-1: Insulin-like growth factor-1; IFGBP-3: Insulin-like growth factor binding protein-3; WHR: Waist-to-hip ratio; BMI: Body mass index.
Table 7  Analysis of serum insulin, insulin-like growth factor-1, insulin-like growth factor binding proteins, and insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio

| Stage | n  | Insulin (mU/L) | IGF-1 (μg/L) | IGFBP-1 (μg/L) | IGFBP-3 (μg/L) | IGF-1/IGFBP-3 |
|-------|----|----------------|--------------|----------------|----------------|----------------|
| T1    | 60 | 7.85 ± 4.87    | 153.52 ± 32.65 | 8.25 ± 1.24    | 8.25 ± 3.25    | 18.61 ± 10.01  |
|       |    | P > 0.05       | P > 0.05     | P > 0.05       | P < 0.05       | P < 0.05       |
| T2    | 362| 10.51 ± 6.03   | 200.37 ± 52.45 | 11.95 ± 2.69   | 5.95 ± 3.26    | 33.68 ± 16.08  |
|       |    | P < 0.05       | P < 0.05     | P < 0.05       | P < 0.05       | P < 0.05       |
| T3    | 193| 11.25 ± 6.57   | 209.69 ± 48.11 | 12.25 ± 3.01   | 5.75 ± 3.86    | 36.47 ± 12.46  |
|       |    | P < 0.05       | P < 0.05     | P < 0.05       | P < 0.05       | P < 0.05       |

IGF-1: Insulin-like growth factor-1; IGFBP-1: Insulin-like growth factor binding protein-1.

demonstrated that serum leptin level in colorectal cancer patients was significantly higher than that in controls.

Furthermore, in this study, we also observed that there was no difference in serum levels of leptin, IGF-1, IGFBP-1 and IGFBP-3 as well as IGF-1/IGFBP-3 ratio between pre- and post-operation colorectal cancer patients or between patients with and without post-surgical metastasis (P > 0.05). We believed that high serum levels of insulin, IGF-1 and IGFBP-3 have no correlation with the disease’s outcome and tumor stage classification in colorectal cancer patients. The underlying mechanisms need to be further investigated. This study also showed that the WHR of colorectal cancer patients were significantly higher than that of healthy controls and it positively correlated with leptin and insulin levels as well as IGF-1/IGFBP3 ratio. This suggests that central obesity is an important risk factor for the initiation of colorectal cancer. The results from MacInnis et al[3] implied that the occurrence of colorectal cancer and human level of obesity are mainly determined by two factors, FFM and WHR, while the data from Moore et al[8] showed that BMI ≥ 30 increased the risks of colon cancer by 50% in 30-54-year-old adults and by 2.4-fold in 55-79-year-old adults. Larger waist size was associated with a two-fold increase in the risk of colon cancer. There was a linear increase in risk with the waist size for both proximal and distal colon cancer[8]. Mao et al[9] believed that obesity induced BMI increase is the major risk factor for colon cancer death. Hou et al[10] also reported a positive correlation between BMI and the incidence of colorectal cancer in Shanghai residents. In this study, we revealed that BMI of colorectal cancer patients showed no statistical difference from that of healthy controls and the relationship of increasing BMI with the initiation of colorectal cancer is of interest for further investigations.

COMMENTS

Background

Insulin-like growth factor-1 (IGF-1) is an important mitogen in the body, which promotes cell proliferation and inhibits apoptosis. Insulin-like growth factor binding protein-3 (IGFBP-3) is an apoptosis inducing cell growth factor and plays its roles through competing with IGF-1 for receptor binding and through regulating local concentration of IGF-1. Increased IGFBP-3 has already been etiologically proved as a risk factor for colorectal cancer. IGFBPs were also considered as regulators of insulin level. But there is no further evidence for them.

Research frontiers

A previous study evaluated the effects of insulin, IGF-1 and IGFBPs on cell growth and proliferation, which played important roles in the etiology of colon cancer. Wei et al believed that hyperinsulinemia, IGF-1 and IGFBP-3 are involved in the pathogenic mechanism of colon cancer and increased colon cancer risk.

Innovations and breakthroughs

A previous study evaluated the effects of insulin, IGF-1 and IGFBPs on cell growth and proliferation, which played important roles in the etiology of colon cancer. The present study aimed to investigate the relationship of changes in serum insulin, IGF-1, IGFBPs, body mass index, waist-to-hip ratio (WHR) with the initiation and progression of colorectal cancer. The authors observed that there were no differences in serum levels of leptin, IGF-1, IGFBP-1 and IGFBP-3 as well as IGF-1/IGFBP-3 ratio between pre-operation and post-operation colorectal cancer patients or between patients with and without post-surgical metastasis.

Applications

The study results suggest that the WHR of colorectal cancer patients was significantly higher than that of healthy controls and it positively correlated with leptin and insulin levels as well as IGF-1/IGFBP3 ratio. IGFBP-1 and IGFBP-3 are mainly determined by two factors, FFM and WHR, while the data from Moore et al showed that BMI ≥ 30 increased the risks of colon cancer by 50% in 30-54-year-old adults and by 2.4-fold in 55-79-year-old adults. Larger waist size was associated with a two-fold increase in the risk of colon cancer. There was a linear increase in risk with the waist size for both proximal and distal colon cancer. Mao et al believed that obesity induced BMI increase is the major risk factor for colon cancer death. Hou et al also reported a positive correlation between BMI and the incidence of colorectal cancer in Shanghai residents. In this study, we revealed that BMI of colorectal cancer patients showed no statistical difference from that of healthy controls and the relationship of increasing BMI with the initiation of colorectal cancer is of interest for further investigations.

Peer review

This paper “Association of Insulin, IGF-1 and IGFBPs with the Risk of Colorectal Cancers” wrote by Bo Jiang et al is good. The investigation is interesting.

REFERENCES

1. Chiu BC, Ji BT, Dai Q, Gridley G, McLaughlin JK, Gao YT, Fraumeni JF, Chow WH. Dietary factors and risk of colon cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2003; 12: 201-208 [PMID: 12646508]
2. Yiu HY, Whitemore AS, Shibata A. Increasing colorectal cancer incidence rates in Japan. Int J Cancer 2004; 109: 777-781 [PMID: 14999789 DOI: 10.1002/ijc.20030]
3. Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B, Neuhausen S. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 1206-1214 [PMID: 15247132]
4. Wei EK, Ma J, Puhlak MN, Rifai N, Fuchos CS, Hainkson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol

WJG | www.wjgnet.com

1612

February 14, 2014 | Volume 20 | Issue 6 |
Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Cell Biol 2001; 21: 151-157 [PMID: 11376125]

Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001; 54: 145-148 [PMID: 11376125]

Liu Z, Usaka T, Watanabe H, Kato N. High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol 2001; 19: 1009-1014 [PMID: 1160502]

MacInnis RJ, English DR, Hopper JL, Hayden AM, Gertig DM, Giles GG. Body size and composition and colon cancer risk in men. Cancer Epidemiol Biomarkers Prev 2004; 13: 553-559 [PMID: 15066919]

Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor JD. Body mass index and colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 2004; 28: 559-567 [PMID: 14770200 DOI: 10.1038/sj.iijo.0802606]

Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183: 1-9 [PMID: 10699960]

Pericleous M, Mandair D, Caplin ME. Diet and supplements and their impact on colorectal cancer. J Gastrointest Oncol 2013; 4: 409-423 [PMID: 24294513]

Kune G, Liu XM. Dietary factors related to colorectal neoplasms. Surg Clin North Am 1993; 73: 13-29 [PMID: 8381240]

Li N, Zhao G, Qiao M, Shao J, Liu X, Li H, Li X, Yu Z. The effects of early life lead exposure on the expression of insulin-like growth factor 1 and 2 (IGF1, IGF2) in the hippocampus of mouse pups. Food Chem Toxicol 2014; 63: 48-52 [PMID: 24208854]

Ito Y, Koessler T, Ibrahim AE, Rai S, Wovler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE, Uribe-Lewis S, Woodfine K, Jagodic M, Nativio R, Dunning A, Moore G, Kleinova E, Bingham S, Pharoah PD, Brenton JD, Beck S, Sandhu MS, Murrell A. Somatically acquired hypomethylation of IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer 2012; 131: E105-E113 [PMID: 21932422 DOI: 10.1002/ijc.26438]

Flood A, Mai V, Pfeiffer R, Kahle L, Rosen CJ, Lanza E, Schatzkin A. Serum concentrations of insulin-like growth factor and insulin-like growth factor binding protein 3 and recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 1493-1498 [PMID: 18559566]

Xuan Y, Han CZ, Du LL. Association between serum insulin and serum lipid substances and breast cancer. Zhongguo Wei Sheng Wu Li Xue Za Zhi 2008; 20: 175-178 [PMID: 19396679]

Gialamas SP, Sergeantis TN, Antonopoulos CN, Desypris N, Chrousos GP, Petridou ET. Circulating leptin levels and risk of colorectal cancer and adenoma: a case-control study and meta-analysis. Cancer Causes Control 2013; 24: 2129-2141 [PMID: 24085585]

Hou L, Ji BT, Blair A, Dai Q, Gao YT, Chow WH. Commuting physical activity and risk of colon cancer in Shanghai, China. Am J Epidemiol 2004; 160: 860-867 [PMID: 15496538]

Jiang B et al. IGF-1, IGFBPs and colorectal cancer [PMID: 12088256]

Stattin P, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, Olsson T, Jellum E. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004; 109: 149-152 [PMID: 14735482 DOI: 10.1002/ijc.11668]

Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119 [PMID: 17973645 DOI: 10.1111/j.1365-2036.2007.03562.x]

Burnstein MJ. Dietary factors related to colorectal neoplasms. Surg Clin North Am 1993; 73: 13-29 [PMID: 8381240]

P-Reviewers: Masaki T, Salceda R
S-Editor: Song XX  L-Editor: Wang TQ  E-Editor: Liu XM
